🔎 Trials Near Me

Pradžia › Atopinis dermatitas (egzema) › Kalifornija

Atopinis dermatitas (egzema) klinikiniai tyrimai Kalifornija

30 tyrimai dėl Atopinis dermatitas (egzema) ieško dalyvių vietose Kalifornija.

Miestai Kalifornija

Oficialus tyrimo tekstas (anglų kalba)

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

  • First OC Dermatology, Irvine
Renkami dalyviai1 fazėLaukiami sveiki savanoriai
Amžius nuo 18 iki 72 · Visoms lytims · Atnaujinta 2026-09-29 · NCT06808477

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

  • Kern Research, Inc.- Site Number : 8400047, Bakersfield
  • Center for Dermatology Clinical Research- Site Number : 8400014, Fremont
  • Dermatology Research Associates - Los Angeles- Site Number : 8400020, Los Angeles
  • ir dar 4
Renkami dalyviaiStebimasis tyrimas
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-09-29 · NCT07290803

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

  • Novartis Investigative Site, Fountain Valley
  • Novartis Investigative Site, Los Angeles
  • Novartis Investigative Site, Sacramento
  • ir dar 2
Renkami dalyviai2 fazė
Amžius nuo 18 iki 100 · Visoms lytims · Atnaujinta 2026-09-28 · NCT06947993

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

  • Enveda Investigative Site, Beverly Hills
  • Enveda Investigative Site, Fremont
  • Enveda Investigative Site, San Diego
  • ir dar 3
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07298395

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

  • Alliance Clinical West Hills (Focus Clinical Research), West Hills
Renkami dalyviai1 fazėLaukiami sveiki savanoriai
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07527923

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

  • Investigational Drug Service - Rady Childrens Hospital-San Diego, San Diego
  • University of California, San Diego/ Rady Children's Hospital - San Diego, San Diego
Renkami dalyviai3 fazė
Amžius nuo 2 iki 11 · Visoms lytims · Atnaujinta 2026-09-25 · NCT06807281

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

  • Marvel Clinical Research, Huntington Beach
  • Metropolis Dermatology - DTLA, Los Angeles
  • Northridge Clinical Trials, Northridge
  • ir dar 1
Renkami dalyviai2 fazė
Amžius nuo 18 iki 64 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07216027

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

  • Investigational Site, Fountain Valley
  • Investigational Site, Los Angeles
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-23 · NCT07003425

The Impact of Dietary Salt on the Severity of Eczema

  • San Francisco VA Medical Center, San Francisco
  • UCSF Mt Zion Campus, San Francisco
Renkami dalyviai4 fazėLaukiami sveiki savanoriai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-10 · NCT07447063

The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease

  • UCSF Mt Zion Campus, San Francisco
  • San Francisco VA Medical Center, San Francisco
Renkami dalyviai4 fazėLaukiami sveiki savanoriai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-09 · NCT07487831

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

  • UCLA Division of Dermatology, Los Angeles
  • Dermatology Research Associate, Los Angeles
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-04 · NCT07223697

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema

  • Northridge Clinical Trials, Northridge
Renkami dalyviai3 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-09-04 · NCT07765888

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

  • Marvel Research, LLC, Huntington Beach
  • Metropolis Dermatology, Los Angeles
  • Dermatology Research Associates, Los Angeles
  • ir dar 4
Renkami dalyviai2 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-08-28 · NCT07599813

Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

  • Allergy and Asthma Medical Group and Research Center, San Diego
Renkami dalyviaiStebimasis tyrimas
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-08-17 · NCT06899204

Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.

  • Integrative Skin Science and Research, Sacramento
Renkami dalyviai4 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-08-13 · NCT07560618

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

  • Inmagene Site 1, Lancaster
  • Inmagene Site 23, Los Angeles
Renkami dalyviai2 fazė
Amžius nuo 18 iki 74 · Visoms lytims · Atnaujinta 2026-08-12 · NCT07037901

A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

  • Enveda Investigative Site, Encinitas
  • Enveda Investigative Site, Los Angeles
  • Enveda Investigative Site, Northridge
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-06 · NCT07643766

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

  • Stanford University School of Medicine /ID# 269622, Palo Alto
  • Integrative Skin Science and Research /ID# 265108, Sacramento
Renkami dalyviai3 fazė
Amžius nuo 2 iki 11 · Visoms lytims · Atnaujinta 2026-08-06 · NCT06461897

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

  • Anaheim Clinical Trials, LLC, Anaheim
  • TCR Medical Corporation, San Diego
Renkami dalyviai1 fazėLaukiami sveiki savanoriai
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-07-22 · NCT06564389

Sodium in the Skin and Atopic Dermatitis

  • San Francisco VA Medical Center, San Francisco
  • UCSF Mt Zion Campus, San Francisco
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius 50 ir vyresni · Visoms lytims · Atnaujinta 2026-07-14 · NCT06998446

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

  • Leo Pharma Investigational site, Palo Alto
  • Leo Pharma Investigational site, Sacramento
  • Leo Pharma Investigational site, San Diego
Renkami dalyviai3 fazė
6 Months – 11 Years · Visoms lytims · Atnaujinta 2026-07-07 · NCT06311682

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

  • Exalt Clinical Research /ID# 281611, Chula Vista
  • Private Practice - Dr. Tooraj Raoof /ID# 263849, Encino
  • First OC Dermatology /ID# 263349, Fountain Valley
  • ir dar 8
Renkami dalyviai3 fazė
Amžius nuo 18 iki 63 · Visoms lytims · Atnaujinta 2026-07-06 · NCT06389136

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

  • University of California, San Diego: Dermatology Clinical Trials Unit, San Diego
Renkami dalyviai1 fazė
Amžius 6 ir vyresni · Visoms lytims · Atnaujinta 2026-07-02 · NCT06504160

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

  • First OC Dermatology, Fountain Valley
  • Center for Dermatology Clinical Research, Inc., Fremont
  • California Allergy and Asthma Medical Group, Los Angeles
  • ir dar 1
Renkami dalyviai2 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-06-15 · NCT06397911

Molecular Signatures of Cutaneous Dupilumab Response

  • University of California, San Francisco, San Francisco
Renkami dalyviai4 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-04 · NCT05858619

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

  • Marvel Clinical Research, Huntington Beach
  • California Allergy and Asthma Medical Group, Los Angeles
  • University Dermatology Trials, INC., Newport Beach
  • ir dar 4
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-05-04 · NCT05995964

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

  • Galderma Investigational Site - 7074, Corona
  • Galderma Investigational Site 8636, Fountain Valley
  • Galderma Investigational Site 8224, Fremont
  • ir dar 4
Renkami dalyviaiStebimasis tyrimas
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-03-13 · NCT06988605

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

  • Corvus Clinical Trials, South San Francisco
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-05 · NCT07441395

Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

  • University of California San Diego (UCSD), La Jolla
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Moterims · Atnaujinta 2025-01-28 · NCT05938478

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

  • Physioseq, LLC /ID# 267266, Sacramento
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2025-01-24 · NCT06524635

Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.